Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.15	$4.05	$1.55 ▼ $4.50	$347.62M	1.18	1.26 million shs	637,488 shs
GALT Galectin Therapeutics	$1.30 -1.5%	$1.43	$0.73 ▼ $3.28	$82.13M	0.62	316,169 shs	104,791 shs
SNDL SNDL	$1.28 -3.0%	$1.42	$1.26 ▼ $2.75	$336.35M	3.68	2.17 million shs	1.77 million shs
TRDA Entrada Therapeutics	$7.97 -8.4%	$9.04	$7.10 ▼ $21.79	$302.49M	0.04	128,905 shs	150,490 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	0.00%	0.00%	+3.49%	+19.94%	+166.03%
GALT Galectin Therapeutics	-1.52%	-17.20%	-2.99%	0.00%	-54.23%
SNDL SNDL	-3.03%	-1.16%	-3.76%	-31.18%	-51.15%
TRDA Entrada Therapeutics	-8.39%	-2.33%	+0.63%	-36.90%	-43.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	1.94 of 5 stars	1.2	4.0	4.2	0.9	0.8	0.0
GALT Galectin Therapeutics	1.0771 of 5 stars	3.0	0.0	0.0	2.5	1.7	0.0
SNDL SNDL	3.07 of 5 stars	3.5	3.0	0.0	2.7	0.0	1.3
TRDA Entrada Therapeutics	3.0579 of 5 stars	3.6	3.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	4.42% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	746.15% Upside
SNDL SNDL	3.00	Buy	$3.63	183.20% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	222.04% Upside

Current Analyst Ratings Breakdown

Latest GALT, CKPT, SNDL, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/31/2025	CKPT Checkpoint Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.80 ➝ $4.80
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/19/2025	SNDL SNDL	ATB Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		$3.50 ➝ $4.00
3/11/2025	CKPT Checkpoint Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.10
3/10/2025	CKPT Checkpoint Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $4.10
3/10/2025	CKPT Checkpoint Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $4.80
2/25/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	8,478.55	N/A	N/A	($0.47) per share	-8.83
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.01) per share	N/A
SNDL SNDL	$927.61M	0.36	N/A	N/A	$3.47 per share	0.37
TRDA Entrada Therapeutics	$172.22M	1.76	N/A	N/A	$7.26 per share	1.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.43	N/A	∞	N/A	N/A	N/A	-659.07%	N/A
GALT Galectin Therapeutics	-$41.07M	-$0.76	N/A	N/A	N/A	N/A	N/A	-163.15%	5/21/2025 (Estimated)
SNDL SNDL	-$127.91M	-$0.29	N/A	N/A	N/A	-12.11%	-8.27%	-6.96%	N/A
TRDA Entrada Therapeutics	-$6.68M	$0.81	5.01	N/A	N/A	25.53%	16.11%	10.39%	N/A

Latest GALT, CKPT, SNDL, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million
3/18/2025	Q4 2024	SNDL SNDL	-$0.01	-$0.19	-$0.18	-$0.19	$248.10 million	$179.06 million
2/27/2025	Q4 2024	TRDA Entrada Therapeutics	-$0.66	$0.03	+$0.69	$0.03	$11.95 million	$12.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
GALT Galectin Therapeutics	N/A	1.13	1.13
SNDL SNDL	0.10	5.61	4.16
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
GALT Galectin Therapeutics	11.68%
SNDL SNDL	N/A
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
GALT Galectin Therapeutics	50.10%
SNDL SNDL	N/A
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	83.76 million	47.81 million	Optionable
GALT Galectin Therapeutics	9	63.18 million	31.32 million	Optionable
SNDL SNDL	580	262.78 million	N/A	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

GALT, CKPT, SNDL, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12 at 5:45 PM | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday

May 5, 2025 | americanbankingnews.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.com

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.com

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

April 29, 2025 | zacks.com

Renaissance Technologies LLC Acquires 72,400 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 27, 2025 | marketbeat.com

Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 17, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.

April 16, 2025 | marketbeat.com

Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMD

March 26, 2025 | nasdaq.com

Entrada receives authorization in the UK to initiate ELEVATE-45-201 study

March 25, 2025 | markets.businessinsider.com

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK

March 24, 2025 | msn.com

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025 | globenewswire.com

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

March 3, 2025 | finance.yahoo.com

Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM

March 1, 2025 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, CKPT, SNDL, and TRDA Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.15 0.00 (0.00%)

As of 05/14/2025 04:00 PM Eastern

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Galectin Therapeutics NASDAQ:GALT

$1.30 -0.02 (-1.52%)

As of 05/14/2025 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

SNDL NASDAQ:SNDL

$1.28 -0.04 (-3.03%)

As of 05/14/2025 04:00 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Entrada Therapeutics NASDAQ:TRDA

$7.97 -0.73 (-8.39%)

As of 05/14/2025 04:00 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time